Ownership history in Clarius Group, LLC Β· 18 quarters on record
This page tracks every 13F SEC filing in which Clarius Group, LLC reported a position in NAUTILUS BIOTECHNOLOGY INC (NAUT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Clarius Group, LLC underperformed the S&P 500 by β12.6% annually on this NAUT position. Timing score: 55% (6/11 decisions correct). Average cost basis: $2.63. Maximum drawdown during holding period: β88.1%.
β Significantly underperformed the S&P 500 by 12.6% ann.
17 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
6 of 11 add/trim decisions correct
Best entry: $0.73 (2025 Q2) Β· Worst: $6.14 (2021 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
10 adds Β· 1 trim. Bought during 7 of 12 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.13% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size